Our research findings support the use of targeted delivery strategies [83] within the context of the Wnt signaling to inhibit TCF7L2 expression as a potential therapeutic approach for treating ccRCC. This evidence concerns the gene TCF7L2 and nonpapillary renal cell carcinoma.